Skip to main content
Premium Trial:

Request an Annual Quote

Oligomerix Lands NIA Grant for Alzheimer's Biomarker Research

NEW YORK (GenomeWeb News) — Oligomerix said today that it has received a $323,000 grant from the National Institutes of Health's National Institute on Aging for research that could lead to diagnostic assays for Alzheimer's disease.

The New York, NY-based company plans to use the Small Business Innovation Research funding to develop a test that could monitor proteins in cerebrospinal fluid and plasma from AD patients. This research will be conducted by researchers at Columbia University Medical Center.

The company said that it will evaluate novel biomarkers by studying protein-protein interactions in search of new ways of diagnosing and monitoring AD.

"Our focus is to develop assays that can be used for drug discovery for AD," Oligomerix CEO James Moe said in a statement. "Any validated assays developed under this program for disease staging or definitive diagnosis of AD will be potential out-licensing opportunities for the company."

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.